Compare Diamondback Energy Inc (FANG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Diamondback Energy Inc trades at $198 (market cap $55.49B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Diamondback Energy Inc is far larger — about 7.4× Spyre Therapeutics Inc. Common Stock's market cap, and Diamondback Energy Inc pays a 2.22% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 70 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FANG | SYRE | |
|---|---|---|
Market Cap | $55.49B | $7.52B |
Volume | 2,752,760 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $213.69 | $108.92 |
52-Week Low | $137.29 | $22.18 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $67.65B | $6.52B |
Dividend Yield | 2.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $197.51, up 1.23% with strong analyst support (90.57% buy rating) and a $232.54 consensus price target. Recent earnings beat expectations in Q1 and Q2 2026, while cash flow from operations improved to $8.76B in 2025. The stock shows bullish technical signals with support at $194 and resistance at $200, though RSI levels indicate potential overbought conditions.
FANG offers growth potential with rising revenue and operational efficiency, but faces risks from oil price volatility and declining profit margins. Institutional buying and positive Permian Basin developments support upside, while insider selling and competitive pressures warrant caution for investors seeking energy exposure.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
